Biopharma ESG Risk: Introducing Our Capsule System for Assessing U.S. Drug Pricing Risk With ICER Cost-Effectiveness Benchmark
Biopharma ESG Risk: Introducing Our Capsule System for Assessing U.S. Drug Pricing Risk With ICER Cost-Effectiveness Benchmark
Drug pricing is complex. Few people know the exact net prices drug wholesalers, pharmacies, pharmacy benefit managers, managed-care organizations, governments, and patients pay once all rebates and discounts are tallied. To simplify the analysis of a company’s drug pricing practices, Morningstar is introducing a capsule numbering system that categorizes companies into one of five buckets.
What's Inside
What's Inside
What capsules we’ve assigned to 18 of the largest biopharma firms in Morningstar’s coverage
How policy restructuring, aggressive private-payer actions, or ESG pressure on the biopharma industry might impact individual firms
How the use of capsules will be embedded into the Sustainalytics ESG Risk Rating analysis and what this could mean moving forward